Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada


You May Also Like

OncoMed Provides Update on Navicixizumab Partnership

REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), ...

resTORbio Reports Second Quarter 2018 Financial Results

Phase 2b results identify dose and patient population for pivotal program with RTB101 Initiation ...